Synthesis and antidepressant and anxiolytic activity of derivatives of pyrazolo[4,3-c]pyridine and 4-phenylhydrazinonicotinic acids

Pharmaceutical Chemistry Journal

Volumn 46, Issue 1, 2012, Pages 15-19

  Zhmurenko, L A ^a   Molodavkin, G M ^a   Voronina, T A ^a   Lezina, V P ^a  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

Antidepressant activity; Anxiolytic activity; Synthesis of 4 phenylhydrazinonicotinic acid derivatives; Synthesis of pyrazolo 4,3 c pyridine 3 ones

Indexed keywords

2,6 DIMETHYL 4 (4 CHLOROPHENYLHYDRAZINO)NICOTINIC ACID ALLYL ESTER; 2,6 DIMETHYL 4 (4 CHLOROPHENYLHYDRAZINO)NICOTINIC ACID AMIDE; 2,6 DIMETHYL 4 (4 CHLOROPHENYLHYDRAZINO)NICOTINIC ACID ETHYL ESTER; 2,6 DIMETHYL 4 (4 CHLOROPHENYLHYDRAZINO)NICOTINIC ACID N ALLYLAMIDE; 2,6 DIMETHYL 4 (4 ETHOXYCARBONYLPHENYLHYDRAZINO)NICOTINIC ACID AMIDE; 2,6 DIMETHYL 4 (4 ETHOXYCARBONYLPHENYLHYDRAZINO)NICOTINIC ACID ETHYL ESTER; 2,6 DIMETHYL 4 (4 ETHOXYCARBONYLPHENYLHYDRAZINO)NICOTINIC ACID N ALLYLAMIDE; 2,6 DIMETHYL 4 (4 NITROPHENYLHYDRAZINO)NICOTINIC ACID ETHYL ESTER; 4 PHENYLHYDRAZINONICOTINIC ACID DERIVATIVE; 4,6 DIMETHYL 2 (4 CHLOROPHENYL) 2,3 DIHYDRO 1H PYRAZOLO[4,3 C]PYRIDINE 3 ONE; 4,6 DIMETHYL 2 (4 ETHOXYCARBONYLPHENYL) 2,3 DIHYDRO 1H PYRAZOLO[4,3 C]PYRIDINE 3 ONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DIAZEPAM; FLUOXETINE; NICOTINIC ACID DERIVATIVE; PYRAZOLO[4,3 C]PYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; INFRARED SPECTROSCOPY; MALE; MUSCLE RELAXATION; NONHUMAN; RAT; SEDATION; TRANQUILIZING ACTIVITY;

EID: 85027957236     PISSN: 0091150X     EISSN: 15739031     Source Type: Journal    
DOI: 10.1007/s11094-012-0726-z     Document Type: Article

References (12)

1. M. S. Allen, P. Skolnick, and J. M. Cook, J. Med. Chem., 35, 368-374 (1992).
2. I.T. Forbes, C.N. Johnson, G. E. Jones, et al., J. Med. Chem., 33, 2640-2645 (1990).
3. N. Yokoyama, B. Ritter, and A. D. Neubert, J. Med. Chem., 25, 337-339 (1982).
4. O.M. Glozman, L. A. Zhmurenko, V. P. Lezina, et al., Khim.-farm. Zh, 35(11), 8- 10 (2001).
5. A. Michaelis, Liebigs Ann. Chem., 366, 324-407 (1909).
6. N. I. Andreeva, Handbook of Experimental (Preclinical) Study of New Drugs [in Russian], R. U. Khabriev (ed.), Meditsina, Moscow (2005), pp. 244-252.
7. R. D. Porsolt, et al., Eur. J. Pharmacol., 47, 379-391 (1978).
8. S. Nomura, J. Shimizu, M. Kinjo, et al., Eur. J. Pharmacol., 83, 171-175 (1982).
9. G. M. Molodavkin, T. A. Voronina, and A. L. Mdzinarishvili, Eksp. Klin. Farmakol., 57(1), 3-5 (1994).
10. T. A. Voronina and S. B. Seredenin, Handbook ofExperimental (Preclinical) Study ofNew Drugs [in Russian], R. U. Khabriev (ed.), Meditsina, Moscow (2005), pp. 253-262.
11. G. M. Molodavkin and T. A. Voronina, Eksp. Klin. Farmakol., 58(2), 54-56 (1995).
12. E. V. Arzamastsev, T. A. Gus'kova, I. V. Berezovskaya, et al., Handbook of Experimental (Preclinical) Study of New Drugs [in Russian], R. U. Khabriev (ed.), Meditsina, Moscow (2005), pp. 41-53.